Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.

Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.

Item
http://www.wikidata.org/entity/Q43034121
Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.The mode and tempo of hepatitis C virus evolution within and among hosts.Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapyMetabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression.NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patientsImpact of host and virus genome variability on HCV replication and response to interferon.Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.The role of HCV proteins on treatment outcomes.Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy.Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma
P2860

Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.

Item
http://www.wikidata.org/entity/Q43034121
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@en
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@nl
type
label
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@en
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@nl
prefLabel
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@en
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Polymorphisms of hepatitis C v ...... ribavirin combination therapy.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698